David Welsh, MD
NPI 1265455232 · Pulmonary Disease Physician · New Orleans, LA
Enrolled with Medicare as Practitioner - Pulmonary Disease · source: CMS PECOS Public Provider Enrollment (2026.04.01)
Provider details
- NPI number
- 1265455232
- Entity type
- Individual
- Primary specialty
- Pulmonary Disease PhysicianAllopathic & Osteopathic Physicians
- Credential
- MD
- Sex
- Male
- Sole proprietor
- No
- License
- 11063R (LA)
Specialties & taxonomies
Allopathic & Osteopathic Physicians
Profile Score
A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.
- Registry tenure25% of score
19 yrs in NPPES registry
- Profile completeness25% of score
100% of core fields populated
- Practice footprint15% of score
1 documented practice location
- Medicare service volume (vs. specialty peers)25% of score
157 Medicare services, 2024 (ranked within specialty)
- Open Payments transparency10% of score
Has Open Payments disclosures (2024)
Medicare volume is ranked against active providers in the same specialty. Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our .
What this provider does (Medicare)
Based on Medicare fee-for-service claims, 2024; not all care is captured.
| Service (HCPCS) | Medicare services | Typical Medicare-allowed (2024) |
|---|---|---|
| Critical Care, First 30-74 Minutes99291 | 50 | $202 |
| Subsequent Hospital Care With Moderate Levelof Medical Decision Making, If Using Time, at Least 35 Minutes99232 | 23 | $76 |
| Test to Determine Lung Volumes Using Sensors94726 | 22 | $11 |
| Test to Examine How Well the Lungs Exchange Gases94729 | 22 | $8 |
| Test to Measure Expiratory Airflow and Volume94010 | 17 | $8 |
| Initial Hospital Care With Moderate Level of Medical Decision Making, If Using Time, at Least 75 Minutes99223 | 12 | $166 |
What this provider prescribes (Medicare Part D)
Top drugs by Medicare Part D claim volume, 2024 · 7 distinct drugs on file.
| Drug | Part D claims (2024) |
|---|---|
| Varenicline Tartrate | 40 |
| Albuterol Sulfatebrand: Albuterol Sulfate Hfa | 28 |
| Ipratropium/Albuterol Sulfatebrand: Combivent Respimat | 24 |
| Fluticasone/Umeclidin/Vilanterbrand: Trelegy Ellipta | 24 |
| Umeclidinium Bromidebrand: Incruse Ellipta | 20 |
| Budesonide/Formoterol Fumaratebrand: Symbicort | 16 |
| Fluticasone/Vilanterolbrand: Breo Ellipta | 15 |
Medicare Part D only. These counts cover prescriptions paid through Medicare Part D in 2024 — they do notinclude cash-pay, commercial-insurance, Medicaid, or Part B–administered drugs, and badly undercount high cash-pay categories (e.g. GLP-1 weight-loss, testosterone, and ED medications). Any drug with 10 or fewer claims is omitted by CMS, and beneficiary counts under 11 are suppressed — so a missing drug means , never zero. This is a factual claims summary, not an endorsement, not medical advice, and not a consumer report. Source: CMS Medicare Part D Prescribers — by Provider and Drug.
Transparency — industry payments
Based on CMS Open Payments, 2024; not all care is captured.
$24 across 1 record (Open Payments 2024)
Open Payments discloses payments and transfers of value (meals, travel, consulting, research, royalties) from drug and device makers to providers. This is a transparency signal, not a verdict — such payments are legal and common, and their presence is neither an endorsement nor a criticism. Source: CMS Open Payments, program year 2024.
Practice location
Mailing address
Registry dates
- Enumerated
- 2006-07-25
- Last updated
- 2014-12-30
Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.